Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy.
OBJECTIVE
To record the effect of pyrazinamide on uric acid in patients of tuberculosis.


METHODS
Descriptive and observational study.


METHODS
Chandka Medical College Hospital, Larkana from February 2000 to January 2003.


METHODS
All patients receiving anti-tuberculosis drugs with pyrazinamide were included. Serum uric acid levels were monitored at weeks 0, 2, 8 and 12 of therapy. Serum creatinine was done at weeks 0, 8 and 12.


RESULTS
Results were reported on 216 patients. Mean uric acid and creatinine levels at the start of therapy, i.e., week '0' were 5.07 -/+ 0.57 mg/dl and 0.87 -/+ 0.11 mg/dl respectively. The results show significant increase in uric acid levels from week '0' to week '2', at the end of week '8', the levels remained elevated and there was no statistical significant difference from that at week '2'. The uric acid levels reduced at week '12' after pyrazinamide was stopped and the difference was significant. Despite that renal function steadily improved with the treatment of tuberculosis to the extent that comparable pre-treatment values were obtained at the end of treatment.


CONCLUSIONS
Anti-tuberculous therapy with pyrazinamide affects the uric acid levels early. This change is reversible after the withdrawal of the agent.
Solangi
Ghulam Akbar
GA
Department of Medicine, Chandka Medical College, Larkana.
Zuberi
Bader Faiyaz
BF
Shaikh
Sikandar
S
Shaikh
Wazir Muhammad
WM
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D011446:Prospective Studies; D011718:Pyrazinamide / Q000009:adverse effects*; D014527:Uric Acid / Q000097:blood
D000995:Antitubercular Agents; D014527:Uric Acid; D011718:Pyrazinamide; D003404:Creatinine